Olr357 inhibitors are a specialized class of chemical compounds that interact with the Olr357 receptor, a protein primarily involved in olfactory signal transduction. These inhibitors are designed to selectively bind to the Olr357 receptor, modulating its activity and thereby altering the receptor's ability to respond to specific odorant molecules. The Olr357 receptor belongs to the G protein-coupled receptor (GPCR) family, a large and diverse group of membrane proteins that play crucial roles in various physiological processes. The Olr357 receptor, like other olfactory receptors, is embedded in the cell membranes of olfactory sensory neurons and is involved in the detection and transduction of odorant signals into neuronal responses. When an odorant binds to Olr357, it induces a conformational change in the receptor, activating a G protein that subsequently triggers a cascade of intracellular events, leading to the generation of an action potential in the olfactory neuron. Olr357 inhibitors act by preventing this binding or by stabilizing the receptor in an inactive conformation, thereby diminishing or completely blocking the signal transduction process.
Chemically, Olr357 inhibitors exhibit a diverse range of structures, reflecting the complexity of the receptor's binding site and the specificity required for effective inhibition. These inhibitors can be small organic molecules, peptides, or even larger biologics, each with distinct mechanisms of action depending on how they interact with the receptor. Structural studies, often involving techniques such as X-ray crystallography or cryo-electron microscopy, are crucial in elucidating the exact binding modes of these inhibitors. Understanding the molecular interactions between Olr357 inhibitors and the receptor can provide insights into the dynamics of olfactory signal transduction, as well as the broader implications for sensory biology. Moreover, the study of Olr357 inhibitors contributes to a deeper understanding of GPCR regulation and the intricate balance between receptor activation and inhibition, which is vital for maintaining the specificity and sensitivity of olfactory responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Inhibits EGFR and HER2 tyrosine kinases, potentially affecting cell growth and proliferation in certain cancers. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Targets EGFR, potentially modulating signal transduction pathways involved in tumor growth. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, potentially influences cell signaling in non-small cell lung cancer. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple tyrosine kinases, potentially impacting cell proliferation and angiogenesis. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Targets VEGFR, FGFR, PDGFR, RET, and KIT, potentially affecting angiogenesis and tumor growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL, KIT, and PDGFR, potentially effective in chronic myeloid leukemia and gastrointestinal stromal tumors. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets BCR-ABL and SRC family kinases, potentially effective in leukemia with specific genetic alterations. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Irreversible inhibitor of EGFR, HER2, and HER4, potentially impacting signal transduction in cancer. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, potentially modifies signaling pathways in non-small cell lung cancer with specific mutations. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Inhibits BRAF V600E kinase, potentially affecting cell growth in melanoma with this mutation. | ||||||